Positive Movement in Silexion Therapeutics' Stock
Silexion Therapeutics Corp. (NASDAQ: SLXN) has experienced a significant rise in its stock price, climbing over 21.72% during pre-market trading. This surge follows the release of promising results from a Phase 2 clinical trial centered on their innovative product, LODER.
Key Findings from the Phase 2 Trial
The analysis revealed an impressive 56% objective response rate (ORR) for patients who received treatment with LODER. Notably, among those whose previously inoperable tumors transitioned to being suitable for resection, the response rate jumped to 67%.
Improved Survival Rates
Silexion previously indicated that patients treated with LODER alongside standard chemotherapy saw a meaningful boost in overall survival. Specifically, this group experienced a 9.3-month increase in survival time compared to those who did not receive LODER treatment.
Enhancing Surgical Options
The latest data underscores LODER's potential to improve tumor resectability, offering additional surgical choices for patients facing pancreatic cancer. This presents a promising alternative for individuals who were previously deemed inoperable.
Advancements in Product Development
Alongside LODER, Silexion Therapeutics is making strides with their next-generation product, SIL-204. This new therapy is specifically crafted to address a wider range of KRAS mutations.
Strategic Partnerships and Growth
In a major strategic move, Silexion Therapeutics merged with Moringa Acquisition Corp, a publicly traded special purpose acquisition company, along with Biomotion Sciences. This merger enabled the newly formed organization to rebrand itself as Silexion Therapeutics.
Current Stock Price Trends
As of the latest updates, SLXN stock was trading at $0.91, reflecting an 18.3% gain during the pre-market session. The ongoing developments paired with encouraging trial outcomes indicate strong potential for future growth.
Frequently Asked Questions
What is the recent stock performance for Silexion Therapeutics?
Silexion Therapeutics' stock has risen over 21.72% in pre-market trading, fueled by positive trial results.
What were the key findings of the Phase 2 trial?
The Phase 2 trial demonstrated a 56% overall response rate, increasing to 67% for patients whose tumors became resectable.
How does LODER impact survival rates?
Patients treated with LODER in combination with chemotherapy experienced an increase in overall survival of 9.3 months.
What advancements is Silexion making in drug development?
Silexion is actively developing SIL-204, which targets a broader array of KRAS mutations for improved treatment options.
What is the current stock price of SLXN?
As of the latest report, SLXN is priced at $0.91 in the pre-market session, reflecting strong interest from investors.
